Everest is listed on the portfolio pages of Arlington Capital Partners (portfolio page) and Quiet Capital (portfolio page). Arlington Capital Partners and Quiet Capital list it as current.
Everest Clinical Research is a global CRO delivering end-to-end clinical trial support to pharmaceutical, biotechnology, and medical device companies.
Source: everestclinical.com, read October 2026
Everest is a Healthcare company. Its owner on record, Arlington Capital Partners, is a leveraged buyout firm founded in 1999, headquartered in Washington, DC, United States, with Approximately $14.0 billion under management. Arlington Capital Partners lists 62 companies in the index, 9 of them in Healthcare. Also backed by Quiet Capital.
Arlington Capital Partners is a Washington, DC-based private equity firm focusing on leveraged buyout and recapitalization investments in middle market companies.
Read the Arlington Capital Partners profileVenture capital firm investing across consumer and enterprise technology.
Read the Quiet Capital profileEverest is listed on the portfolio pages of Arlington Capital Partners (portfolio page) and Quiet Capital (portfolio page). Arlington Capital Partners and Quiet Capital list it as current.
Everest is in Healthcare. Classified from the owner's portfolio label.
Arlington Capital Partners is headquartered in Washington, DC, United States.
Arlington Capital Partners lists 8 other Healthcare companies in the index, including Afton Scientific, AVS Bio, CBSET, Cordica Medical and Grand River Aseptic Manufacturing (GRAM).
Everest's website is https://everestclinical.com/.
6 of 61 shown
See the full Arlington Capital Partners portfolio.
6 of 300 shown
See the full Quiet Capital portfolio.
Browse PE-backed companies.
